NASDAQ: KPTIKaryopharm Therapeutics Inc Stock
$9.55-0.22 (-2.25%)
Updated Jul 1, 2026
KPTI Price
$9.55
Fair Value Price
N/A
Market Cap
$216.43M
52 Week Low
$3.65
52 Week High
$10.99
P/E
-0.59x
P/B
-0.81x
P/S
0.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$151.12M
Earnings
-$194.97M
Gross Margin
96%
Operating Margin
-97.64%
Profit Margin
-129%
Debt to Equity
-1.5
Operating Cash Flow
-$59M
Beta
1.26
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KPTI Overview
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KPTI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KPTI
Ranked#92 of 465
Ranked#92 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.51 | A | |
| $11.00 | A | |
| $15.80 | A |
Be the first to know about important KPTI news, forecast changes, insider trades & much more!
KPTI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KPTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPTI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KPTI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KPTI due diligence checks available for Premium users.
Valuation
KPTI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.59x
Industry
17.58x
Market
8.54x
KPTI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.81x
Industry
5.43x
KPTI's financial health
Profit margin
Revenue
$35.1M
Net Income
-$22.4M
Profit Margin
-63.9%
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KPTI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$131.4M
Liabilities
$397.1M
Debt to equity
-1.5
KPTI's short-term assets ($126.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPTI's long-term liabilities ($279.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPTI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.7M
Investing
$3.2M
Financing
$49.8M
KPTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KPTI vs Biotech Stocks
Karyopharm Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.